Equities research analysts forecast that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report $1.10 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $1.30 million and the lowest is $890,000.00. Xeris Pharmaceuticals posted sales of $800,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The firm is scheduled to announce its next earnings report on Wednesday, March 4th.
On average, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current fiscal year, with estimates ranging from $1.46 million to $2.20 million. For the next financial year, analysts forecast that the company will report sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.20 million.
A number of equities analysts recently issued reports on XERS shares. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research raised Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 16th. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Mizuho reissued a “buy” rating and issued a $22.00 price objective on shares of Xeris Pharmaceuticals in a report on Thursday, November 21st.
XERS stock traded up $0.14 on Friday, reaching $8.94. The company’s stock had a trading volume of 125,806 shares, compared to its average volume of 196,196. Xeris Pharmaceuticals has a 52 week low of $6.85 and a 52 week high of $20.90. The company has a market capitalization of $241.07 million, a P/E ratio of -1.79 and a beta of -0.39. The firm has a fifty day moving average of $8.34 and a two-hundred day moving average of $10.21. The company has a debt-to-equity ratio of 1.33, a current ratio of 5.96 and a quick ratio of 5.96.
In other news, insider Paul R. Edick purchased 17,935 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now owns 172,935 shares in the company, valued at approximately $1,478,594.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steven Prestrelski sold 27,700 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $9.00, for a total value of $249,300.00. Corporate insiders own 7.43% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY bought a new position in Xeris Pharmaceuticals during the 3rd quarter valued at $100,000. Millennium Management LLC bought a new stake in shares of Xeris Pharmaceuticals during the 3rd quarter worth $918,000. IHT Wealth Management LLC boosted its stake in shares of Xeris Pharmaceuticals by 39.4% during the 3rd quarter. IHT Wealth Management LLC now owns 57,028 shares of the company’s stock worth $561,000 after acquiring an additional 16,114 shares in the last quarter. State Street Corp boosted its stake in shares of Xeris Pharmaceuticals by 17.0% during the 3rd quarter. State Street Corp now owns 466,451 shares of the company’s stock worth $4,585,000 after acquiring an additional 67,820 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Xeris Pharmaceuticals during the 2nd quarter worth $118,000. 66.37% of the stock is owned by hedge funds and other institutional investors.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: Key terms to understand channel trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.